IDORSIA
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.
IDORSIA
Industry:
Biotechnology Health Care
Founded:
2017-06-01
Status:
Active
Contact:
41 58 844 00 00
Email Addresses:
[email protected]
Total Funding:
1.44 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Font Awesome Apache
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
Swords Labs
Bristol-Myers Squibb is a biopharma company that works to discover, and deliver innovative medicines that help patients fight disease.
TransGenex Nanobiotech
TransGenex Nanobiotech is to discover, develop and commercialize nano-scale technologies for novel, cost-effective diagnostic.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-07-23 | Vaxxilon | Vaxxilon acquired by Idorsia | N/A |
Investors List
CARB-X
CARB-X investment in Grant - Idorsia
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-09-20 | Santhera Pharmaceuticals | Idorsia investment in Post-IPO Equity - Santhera Pharmaceuticals | 20 M CHF |